Affimed Announces Publication of AFM24 Clinical Abstracts for the Annual Meeting of the American Society of Clinical Oncology
25 mai 2023 17h00 HE
|
Affimed N.V.
AFM24-101 phase 1/2 results in 10 patients from the non-small cell lung cancer (NSCLC) cohort demonstrated clinical activity and a well-managed safety profile in heavily pretreated patients with EGFR...
Affimed Reports First Quarter 2023 Financial Results and Highlights Operational Progress
23 mai 2023 06h30 HE
|
Affimed N.V.
AFM13 combination with AB-101 NK cells: Received IND clearance from the FDA for a phase 2 clinical trial investigating the combination therapy in relapsed/refractory (r/r) classical Hodgkin Lymphoma...
Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy
23 mai 2023 06h15 HE
|
Affimed N.V.
Phase 2 combination study of AFM13 with AB-101 in relapsed or refractory (r/r) classical Hodgkin Lymphoma (cHL) will be an open-label, multi-center, multi-cohort study with a safety run-in followed by...
Affimed Announces Annual General Meeting of Shareholders
22 mai 2023 06h30 HE
|
Affimed N.V.
HEIDELBERG, Germany, May 22, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
Affimed to Report First Quarter 2023 Financial Results & Corporate Update on May 23, 2023
16 mai 2023 06h30 HE
|
Affimed N.V.
HEIDELBERG, Germany, May 16, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
Affimed Announces Abstracts at the Annual Meeting of the European Hematology Association
11 mai 2023 10h05 HE
|
Affimed N.V.
A post-hoc subgroup analysis from the AFM13 REDIRECT study in patients with relapsed/refractory (r/r) peripheral T cell lymphoma (PTCL) is accepted as a poster presentationA trial in progress abstract...
Affimed Announces AFM24 Clinical Abstracts Accepted for the Annual Meeting of the American Society of Clinical Oncology (ASCO)
26 avr. 2023 10h00 HE
|
Affimed N.V.
AFM24-101 phase 1/2 interim results from the non-small cell lung cancer cohort accepted for poster presentationAFM24-101 phase1/2 interim results from the colorectal cancer cohort accepted for online...
Affimed Shares Preclinical Data on AFM13’s Mechanism of Action Demonstrating Its Potential to Induce Serial Killing at the American Association for Cancer Research Annual Meeting
17 avr. 2023 16h05 HE
|
Affimed N.V.
The poster presentation highlights the relevance of CD16A shedding for serial killing by AFM13-engaged natural killer (NK) cellsIt demonstrates the potential of AFM13 to induce serial killing, even in...
Affimed Presents Final Data Demonstrating Safety and Efficacy of AFM13 Phase 2 REDIRECT Study in Patients with Heavily Pretreated Relapsed or Refractory Peripheral T Cell Lymphoma at the American Association for Cancer Research Annual Meeting 2023
16 avr. 2023 15h00 HE
|
Affimed N.V.
AFM13 demonstrated robust activity on the primary end point with an objective response rate (ORR) of 32.4% and 10.2% complete response rate (CR) in Intent to Treat (ITT) populationPatients with...
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
06 avr. 2023 16h05 HE
|
Affimed N.V.
HEIDELBERG, Germany, April 06, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...